Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Gene editing stories

Nov 10, 2026

Beam Therapeutics base-editing sickle cell therapy succeeds in pivotal trial

Beam Therapeutics announced its base-edited sickle cell therapy met its primary endpoint in a Phase 1/2 clinical trial, potentially positioning it as a third one-time curative therapy for the disease.

Nov 10, 2026·2 sources
00
Oct 28, 2026

FDA releases guidance for individualized gene editing therapies

The FDA published new guidance establishing an approval framework for personalized gene editing treatments that could benefit different patient subsets with the same disease, creating a 'plug and play' pathway to accelerate individualized therapies.

Oct 28, 2026·2 sources
00
Jul 21, 2026

Broad Institute, Boston Children's Hospital, and Jackson Laboratory Launch $160 Million Center for Rare Disease Gene Therapies

Three major research institutions announced the creation of the Center for Therapeutic Genetics, a nonprofit collaboration aimed at developing standardized genetic medicines, including base and prime editing, for rare and ultra-rare diseases that currently lack treatments.

Jul 21, 2026·9 sources
00
Jul 9, 2026

ARPA-H Launches $160 Million Gene Editing Drug Development Program

The Advanced Research Projects Agency for Health (ARPA-H) has launched a $160 million initiative to fund seven groups over five years to develop custom gene editing drugs, aiming to replicate successes like the Baby KJ case.

Jul 9, 2026·1 source
00
Apr 19, 2026

Breakthrough Prize Awards $3 Million to Researchers Behind First Sickle Cell CRISPR Therapy

Dr. Swee Lay Thein and Dr. Stuart Orkin received the $3 million Breakthrough Prize in Life Sciences for research that led to the development of the first CRISPR-based therapy for sickle cell disease.

Apr 19, 2026·1 source
00

Top claims

  • ▪Beam Therapeutics plans to submit an approval application for risto-cel to the U.S. Food and Drug Administration as early as the end of 2026
  • ▪Beam Therapeutics announced its base-editing treatment ristoglogene autogetemcel met its primary endpoint of freedom from severe vaso-occlusive crises
  • ▪If approved, risto-cel would enter a sickle cell treatment market that includes approved genetic therapies Casgevy and Lyfgenia, alongside hydroxyurea, l-glutamine, blood transfusions, and stem cell transplants

Subtopics

Drug Policy, Pricing & Approval4Drug Approval and Clinical Trials3Gene therapy3Rare diseases2Biotech innovation1Clinical Genomics & Genetics1Clinical trial endpoints1Clinical trials1Drug development1FDA regulation1FDA regulatory approval1Federal agencies1Genetic diseases1Government and Regulatory Policy1Hematology1Personalized medicine1Precision medicine1Washington D.C.1

Related timelines

Congress

110 stories

Ebola outbreak

85 stories

Iran War

209 stories

Russia-Ukraine war

136 stories

Strait of Hormuz blockage

148 stories